Drugs / MelCancerVac
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00442754 | Dec 2006 → Nov 2009 | non-small cell lung carcinoma | Herlev Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00311272 | Nov 2004 → Sep 2007 | colorectal neoplasm | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MelCancerVac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00442754 ↗ |
| Known as | Allogeneic Tumour Lysate | “Allogeneic Tumour Lysate (MelCancerVac)” NCT00442754 ↗ |
| Modality | Vaccine | “dendritic cell based cancer vaccine” PMID 20816019 ↗ Sep 2010 |
| Route | Subcutaneous | “subcutaneaus, /once weekly /4 wks then /4 weekly” NCT00442754 ↗ |